Phathom Pharmaceuticals, Inc.
Cash Flow Statement
| Line Item | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-91.4M | $-82.9M | $-79.6M | $-43.2M | $-41.0M | $-37.8M | $-55.0M | $-51.1M |
| Depreciation & Amortization | $200.0K | $214.0K | $229.0K | $100.0K | $100.0K | $146.0K | $168.0K | $175.0K |
| Depreciation | — | — | — | $100.0K | $100.0K | $100.0K | $200.0K | $200.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $6.1M | $5.6M | $24.6M | $6.1M | $7.3M | $7.0M | $6.7M | $5.8M |
| Net Cash from Operating Activities | $-70.7M | $-69.0M | $-43.8M | $-31.9M | $-22.2M | $-39.7M | $-41.0M | $-35.0M |
| Investing Activities | ||||||||
| Capital Expenditures | $46.0K | $40.0K | $475.0K | $939.0K | $6.0K | $214.0K | $412.0K | $134.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-46.0K | $-40.0K | $-475.0K | $-939.0K | $-6.0K | $-214.0K | $-412.0K | $-134.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $24.8M | $9.9M | $212.0M | $13.0K | $141.5M | $14.1M | — | — |
| Net Change in Cash | $-46.0M | $-59.2M | $167.7M | $-32.8M | $119.3M | $-25.8M | $-41.5M | $-10.6M |
| Free Cash Flow | $-70.8M | $-69.1M | $-44.3M | $-32.9M | $-22.2M | $-39.9M | $-41.5M | $-35.2M |